Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorThe University of Queensland

About this trial

The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD patients with memory problems will be compared to PD patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in PD. This information will be useful for future clinical trials to target drugs to these brain regions.

Eligibility criteria

Qualifiers

Parkinson's Disease patients with amnestic Mild Cognitive Impairment

Parkinson's Disease patients with no memory impairment

Healthy volunteers

All participants must be eligible to take MRI scans

Disqualifiers

Dementia

Contraindication to having MRI

Bipolar disorder, Schizophrenia, Alcohol or substance abuse

Major depression

Trial design

Treatments tested in this trial

  • Levetiracetam
  • Placebo

Treatment groups

28 Participants
are divided into 2 treatment groups

Sponsors and collaborators

The University of Queensland

Lead sponsor

Queensland University of Technology

Collaborator

Johns Hopkins University

Collaborator

Cleveland Clinic Lou Ruvo Center for Brain Health

Collaborator

Royal Brisbane and Women's Hospital

Collaborator